Dysport (abobotulinumtoxinA) - (C-BEOND)

July 9, 2026: Ipsen (Euronext: IPN; OTC: IPSEY) reported positive topline Phase III results from its BEOND migraine program evaluating Dysport (abobotulinumtoxinA) for prevention of episodic and chronic migraine in adults. Both randomized, multicenter, placebo-controlled trials—E-BEOND (episodic migraine; NCT06047457) and C-BEOND (chronic migraine; NCT06047444)—met their primary endpoints, showing a reduction in monthly migraine days versus placebo.

Ipsen stated E-BEOND is the first Phase III trial where a botulinum toxin demonstrated statistically significant efficacy in episodic migraine, and that BEOND is the first Phase III program to show efficacy of a botulinum toxin in both episodic and chronic migraine prevention.

Across both trials, Dysport was well-tolerated with safety consistent with its known profile and no new or unexpected safety signals. The program enrolled 1,510 patients across 120 centers; the primary endpoint was change from baseline in monthly migraine days at week 24 (measured over weeks 21–24). An extension phase (all participants receive Dysport for two treatment cycles) continues to week 48. Detailed results are planned for presentation at a future scientific congress.